Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Company facts
| Company | Bristol-Myers Squibb Company |
|---|---|
| Symbol | BMY |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $130.22B (Massive market data, 2026-09-10) |
| Employees | 32,500 |
| Country | United States |
| Website | https://www.bms.com |
Trading — Bristol-Myers Squibb Company
| Last price | $63.64 |
|---|---|
| Change | -0.17% |
| Previous close | $63.75 |
| Day range | $63.27 – $64.20 |
| 50-day average | $63.28 |
| 200-day average | $58.41 |
| Average volume | 13,227,627 |
Price basis: 2026-09-11T21:00:34.069628+00:00
Valuation and financial health
| Earnings per share | $4.54 |
|---|---|
| Price / book | 5.83 |
| Price / cash flow | 10.19 |
| Enterprise value / EBITDA | 11.05 |
| Enterprise value / sales | 3.35 |
| Debt / equity | 1.93 |
| Current ratio | 1.53 |
| Dividend yield | 3.91% |
| Free cash flow | $11.44B |
| Cash ratio | 0.47 |
| Enterprise value | $164.62B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-29 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $1.68 |
| Year-ago EPS | $1.63 |
| Analyst estimates | 9 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for BMY are on the IntelTrends dashboard.